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Erythropoietin-Induced Activation of STAT5 Is Impaired in the 
Myelodysplastic Syndrome
■
By Lies H. Hoefsloot, Martine P. van Amelsvoort, Lianne C.A.M. Broeders, Dorien C. van der Plas, Kirsten van Lorn, 
Hans Hoogerbrugge, Ivo P. Touw, and Bob Lowenberg
Patients with myelodysplastic syndrome (MDS) have inef­
fective in vivo and in vitro erythropoiesis, characterized by 
an impaired response to erythropoietin (Epo). We examined 
proliferation and maturation of MDS marrow cells in re­
sponse to Epo in more detail. Epo-dependent DNA synthesis 
as well as induction of GATA-1 binding activity in marrow 
cells from 15 MDS cases were severely reduced as compared 
with normal bone marrow (NBM). Additionally, the appear­
ance of morphologically identifiable erythroid cells was de­
creased in MDS cell cultures. These data indicate that both 
the Epo-dependent proliferation as well as the differentia­
tion induction by Epo is suppressed. To study more up­
stream events of the Epo signal transduction route we inves­
tigated activation of the signal transducer and activator of 
transcription (STAT) 5. In all 15 MDS samples tested, STAT5 
activation was absent or greatly suppressed in response to 
Epo. In contrast, interleukin-3 induced a normal STAT5 re­
sponse in MDS cells. Further, in MDS the subset of CD71+ 
BM cells that is phenotypicaily similar to Epo-responsive 
cells in normal marrow, was present. We conclude that the 
Epo response in MDS is disturbed at an early point in the 
Epo receptor (EpoR) signal transduction pathway.
© 1997 by The American Society of Hematology.
HE MYELODYSPLASTIC syndromes (MDS) consti­
tute a heterogeneous group of disorders of the hemato­
poietic pluripotent stem cell, characterized by ineffective 
hematopoiesis.1 In the majority of cases anemia is an early 
and prominent clinical symptom. In a considerable number 
of cases the disease progresses to acute leukemia. Bone mar-
binding, even though some reports would suggest the possi­
ble involvement of another receptor chain.16'21 Dimerization 
is essential for receptor function.22'24 Upon binding of Epo, 
the Janus kinase JAK2 is rapidly activated via the membrane- 
proximal region of the cytoplasmic domain of the receptor.25'27 
JAK2 activation leads to the tyrosine-phosphorylation of
row (BM) biopsy samples from MDS patients generally several proteins, including the EpoR itself.28'31 Recent data 
show normocellularity or hypercellularity with active eryth- have shown that one of the activated proteins is STAT5.32,33
Two forms of STAT5 (STAT5A and STAT5B) derived fromropoiesis. When BM cells from MDS patients are cultured 
in vitro in the presence of erythropoietin (Epo), the formation 
of erythroid colonies is reduced as compared with colony 
formation by cells from normal marrow.2'6 Ineffective eryth­
ropoiesis is not due to a lack of Epo. Patients with MDS
two different genes have been described, which are highly 
homologous.34 Preliminary evidence indicates that STAT5 
is involved in proliferation signaling from the interleukin-3 
(IL-3) receptor.35 Further, it has been suggested that STAT5
have normal or elevated serum levels of Epo,7’8 and treatment may inhibit Epo-induced differentiation.36
with pharmacological doses of Epo only infrequently im­
proves the anemia significantly .‘J To elucidate the mechanism 
of impaired erythropoiesis in MDS, we set out to investigate 
the role of the Epo receptor (EpoR) and its signal transduc­
tion.
Epo, the major regulator of erythropoiesis, is involved in 
survival, proliferation, and differentiation of erythroid pro­
genitors. The EpoR is expressed at relatively low levels on 
BFU-E (burst-forming units-erythroid, erythroid progeni­
tors), but expression increases with erythroid maturation to­
ward late ery throb lasts. EpoRs are lost on more mature ery­
throid cells.10'13 The EpoR is a member of the hemopoietin 
and cytokine receptor super-family.14,15 It is currently as­
sumed that the receptor forms a homodimer after ligand
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One of the specific events during erythroid differentiation 
is the expression of the transcription factor GATA-1.37 
GATA-1 upregulates the expression of ery thro id-specific 
genes, including the gene for EpoR and the GATA-1 gene. 
GATA-1 expression levels are low in progenitor cells, but 
increase dramatically when the cells are induced to differen­
tiate along the erythroid lineage.38,39 During differentiation 
to myeloid cells, expression of GATA-1 is shut off/10 When 
erythroid progenitors derived from normal blood are cultured 
in the presence of Epo, GATA-1 induction can be shown at 
day 3.3MI Thus, EpoRs may be upregulated by GATA-1, 
whereas activation of EpoR may enhance GATA-1 expres- 
sion.
Recently we have shown that EpoRs are present in normal 
numbers on marrow cells of patients with MDS, and that the 
1 itrand binding capacity of the receptor is intact.4'
variants of the receptor have been described.’14,45
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In
MDS cases, we have not found aberrant splice variants of the 
EpoR.43 In this report we further delineate the consequences 
of Epo stimulation of MDS marrow. We show that the per­
centages of erythroid cells increase in Epo-stimulated normal
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row. In contrast to NBM, there is hardly any induction of 
GATA-1 binding activity by Epo in MDS marrow. Further­
more, in most MDS cases Epo failed to activate STAT5 in 
marrow cells, although in these cells STAT5 can readily be 
activated by IL-3. Finally, we show that the inability of Epo 
to activate STATS is not caused by the absence of the relevant 
cells in MDS. The subpopulation capable of Epo-speciiic
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Table 1. Patient Characteristics and Erythroid Colony Formation
Patient
Age/
Sex Karyotype
FAB
Subtype BFU-E*
1 79/M 46,XV RA 40
2 80/M 46,XY RA 0
3 80/F 46,XX RA 40
4 38/M 46,XY RARS 225
5 69/M 46,XY RAEB 0
6 33/F 46,XX t(3,12),del 7 RAEB 0
7 67/M 47,XY,+8(62%);46,XY(38%) RAEB 0
8 63/M 46,XY RAEB 8
9 67/F 47,XX,+8(91%);46,XX(9%) RAEB 5
10 67/M 46,XY,del(5)(q13q35),--7,-l-8,~16, 
add19(?p or q 13 ),-20 , 
-l-R<95%);46,XY(5%)
RAEB-t 10
11 83/M NA RAEB-t 0
12 68/M 46,XY(3% ) ;44-48,XY, - 4 , - 1 6 ,  
-18(50% };45-49,XY,—4 ,-1 6 ,  
-18,5q-,7q-,13q-(47%)
RAEB-t NA
13 68/M 46,XY(90%);47-48,XY,+8(10%) RAEB-t 18
14 27/M 46,XY RAEB-t 9
15 42/M 46,XY RAEB-t 0
16 64/M 46,XY(9%)46,XY,9q-(91%) CMML 0
17 76/M 47,XY,+8 CMML 45
18 62/M 46,XY CMML 5
19 60/M 46,XY,inv4( p i 5.3q 11 )c CMML 15
20 46/M 46,XY CMML 18
21 67/M 46,XY CMML 3
GATA- J induction. NBM and MDS cells were incubated over­
night in liquid medium without growth factor at a cell concentration 
of 0.5 to 1.0 X 106 cells/mL. The next day the following combina­
tions of growth factors were added: Epo (1 U/mL), IL-3 (2.5 ng/ 
mL), stem cell factor (SCF) (100 ng/mL), Epo + IL-3, and Epo + 
SCF, or none. At the time of harvest, cells were counted, cy to spins 
were made, and the bulk of cells was used to isolate nuclear proteins. 
Nuclear extracts were prepared as described.'*50 In brief, cells were 
collected by centrifugation, resuspended in buffer A (10 mmol/L 
HEPES [pH 7.8], 10 mmol/L KC1, 0.1 mmol/L EDTA, 0.1 mmol/ 
L EOTA, 1 mmol/L dithiothreitol, 1% Pefabloc SC LBoehringer, 
Germany 1, 50 /jg/mL aprotinin, 50 ¿tg/tnL leupeptin, 50 /j.g/mL baci­
tracin, and 50 ¿¿g/mL iodoacetamide) and incubated for 10 minutes 
on ice. Nonidet P-40 (Sigma, St Louis, MO) was added to a final 
concentration of 0.6%, and nuclei were spun down for I minute at 
10,000#. Nuclear proteins were extracted by i of C
Abbreviation: NA, not available. 
* Colonies per 10s cells.
STAT5 activation in NBM has a distinct immunophenotype 
and these cells are present in MDS marrow.
MATERIALS AND METHODS
(20 mmol/L HEPES [pH 7.8], 0.4 mol/L NaCl, I mmol/L EDTA, 
1 mmol/L EGTA, 1% Pefabloc SC, 50 //g/mL aprotinin, 50 /¿g/mL 
leupeptin, 50 ¡j.g/rnL bacitracin, and 50 /ug/mL iodoacetamide), and 
rocking incubation for 15 minutes at 4°C. Extracts were cleared by 
5 minutes of centrifugation at 15,000 rpm. The presence of GATA- 
binding proteins in the nuclear extracts was determined by electro­
phoretic mobility shift assay (EMSA), using a synthetic oligonucleo­
tide probe from the /3-globin region, containing the GATA-binding 
consensus sequence. Three to 5 yL of extract was incubated for 20 
to 30 minutes with 0,2 ng of ‘,2P-labeled (10,000 to 20,000 cpm) 
double-stranded oligonucleotide, in the presence of excess aspecific 
competitor [2 /jg poly(dl-dC)] in 20 ¡iL binding buffer (10 mmol/ 
L Tris hydrochloride [pH 7.6], 100 mmol/L KCl, 5 mmol/L MgCL, 
1 mmol/L EDTA, 12.5% glycerol, 1 mmol/L dithiothreitol) and then 
separated on a 8% polyacrylamide gel in I X  Tris-Borute/EDTA 
electrophoresis buffer (TBE).
STAT-protein activation. After overnight incubation in serum 
free medium/1' NBM or MDS cells were procured, counted, and 2 
to 5 X  106 cells were incubated for the desired time in the absence 
or presence of growth factor
near extracts were mi as
: 100 U/mL. IL-3: 2.5 /./g/ml.).
,i 1,112 leading to
Patient material. BM cells were collected from 21 patients with 20 fjL final extract. EMSA was performed in the presence of excess 
MDS. Patients were classified according to the criteria of the French-
American-British (FAB) group as refractory anemia (RA, n = 3), 
refractory anemia with ring sideroblasts (RARS, n = 1), refractory 
anemia with excessive blasts (RAEB, n = 5), refractory anemia with 
excessive blasts in transformation (RAEB-t, n = 6), and chronic 
myelomonocytic leukemia (CMML, n = 6). NBM was obtained 
from BM transplantation donors after informed consent. Mononu­
clear cells were collected, and cryopreserved as described pre­
viously/17
Erythroid colony culture. Erythroid colony formation was as­
sayed in methylcellulose cultures supplemented with 1 U/mL Epo 
and 2.5 ng/mL IL-3 as previously described.*
DNA synthesis assay. NBM and MDS cells were incubated over­
night (1 to 2 x I0h cells/mL) in liquid medium (Iscove’s modified 
Dulbecco’s medium, supplemented with bovine serum albumin 
[BSA], transferrin, lecithin, sodium selenite, and /?-mercaptoethanol, 
and 30% fetal calf serum'1”). The next morning, cells were diluted 
to 2 x 10s cells/mL and cultured in the presence or absence of Epo 
(1 U/mL). Irradiated cells were used as background controls. After 
3 days, 'H-TdR (0.1 /j,Ci/well) was added for 8 hours. Incorporation 
was measured by liquid scintillation counting as previously de- 
scribed/,,) Cells were procured on nitrocellulose filters and incorpo­
rated label was counted in a /?-p!ate scintillation counter (LKB, 
Bronna, Sweden). To compensate for spontaneous incorporation,
, ob-
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tained by dividing the counts incorporated in the presence of Epo 
by the counts incorporated in medium alone.
Fig 1. Epo-induced activation of DNA synthesis In MDS and NBM. 
Results are given from experiments in 15 MDS patients (1), numbers
correspond to Table 1) and 11 NBM samples (■). Epo was added for
3 days.
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Table 2. Fraction of Erythroid Cells Recovered From Epo-Stimulated Cultures of Normal and MDS Marrow
Growth
Factor
Added
NBM RA RAEB RAEB-t CMML
1 2 3 1* 2* 6* 7 * 8* 10* 11* 13* 14* 15* 17* 21*
— 1,2 0.7 0.1 1.1 0,1 0 NA 0.2 0.2 0 0.4 0.4 0.5 0.1 0.1
Epo 2.7 2.5 0.9 0.6 0.2 0.2 0 0.4 0.1 0.5 0.9 0.4 0.6 0 0.7
Epo + IL-3 5.3 8.5 1.6 0,5 0.1 0 0.1 0.2 0.2 0 0.9 0.4 0.2 0.1 0.4
Epo -b SCF 9.6 3.0 2.0 0.7 0.1 0.5 0.1 0.1 0.1 0 1-1 0.3 0.2 0 0.2
IL-3 1.2 0.8 0.8 0.7 0.1 0.8 0 0.1 0 0 0.2 0.1 0.5 0 0.5
SCF 1.2 0.6 0.7 0.5 0.1 0.3 NA 0.1 0.1 0 0.5 0.1 0.5 0 0.7
Cells were incubated for 72 hours in the presence of the indicated growth factors. Epo, 1 U/mL; IL-3, 2.5 ng/mL; SCF, 100 ng/mL. 
Abbreviation: NA, not available.
* Case of MDS (see Table 1).
a specific competitor |poly(dI-dC)J on 3 ¡uL extract, and probe-protein 
complexes were separated at 4°C on a 5% polyacrylamide gel in
0.25X TBE, containing 5% glycerol. For supershift assays, specific 
antibodies were added lor 1 hour before the incubation with probe. 
Antibodies used were against sheep STAT5,5"’ and antibodies against 
human STAT5A and STAT5B, respectively. STAT5 was detected 
using a synthetic oligonucleotide probe from the ^-casein promoter
(5-AGATTTCTAGGAATTCAATCC-3').54
Analysis of morphology. Differential counts were made on cy- 
tospins of 1 to 4 X 104 cells, stained with May-Grimwald-Giemsa. 
The total amount of cells in the erythroid compartment of a given 
sample was then obtained by multiplying the absolute cell number 
with the percentage of erythroid cells. The fraction of recovered 
erythroid cells was calculated by dividing the total erythroid cells 
in a sample by the total amount of erythroid cells at t = 0.
Sorting and FACScan analysis. Thirty to 60 X I O'1 NBM cells
were labeled in a three-step procedure, 30 minutes per incubation, 
in phosphate-buffered saline containing 1% BSA and 1% preimmune 
rabbit serum (PBR). First step, mouse anti-human glycophorin A 
(GPA) monoclonal antibody; second step, rabbit anti-mouse Ig con­
jugated with RPE (RAM-PE) (Dako, Glostrup, Denmark); third step, 
mouse anti-transferrin receptor-FITC (CD71-FITC) (Becton Dickin­
son, San Jose, CA). In between, cells were washed twice in PBR. 
As controls, 1 X I0f> cells were labeled with CD71-FITC or GPA/ 
RAM-PE. Finally, cells were resuspended in PBR, and sorted on a 
FACSvantage (Becton Dickinson). Analysis of data was done with the 
Lysis software program (Becton Dickinson). After sorting, cells collected 
in all four windows were counted, and cytospins were made. The bulk 
of cells was divided in three portions, and incubated for 15 minutes 
with no factor, Epo (100 U/mL), or IL-3 (2.5 ¿¿g/mL). Extracts were 
made as described above, leading to 10 pL final volume. EMSA was 
performed with 5 to 7 ¡jL extract, in the same way as described above.
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Fig 2. Induction of GATA-binding in MDS and NBM. Cells were obtained and extracted at t = 0 (lanes 1, 8, 15), and after culture for 3 days 
with no factor (lanes 2, 9, 16) Epo (lanes 3, 10, 17), Epo -h IL-3 (lanes 4, 11, 18) Epo + SCF (lanes 5, 12, 19), IL-3 (lanes 6,13, 20), and SCF (lanes
7, 14, 21). Nuclear extracts of equivalent amounts of marrow cells from two MDS patients (no. 19, CMML; and no. 7, RAEB) and one NBM 
were incubated with the /S-globin probe and run on a nondenaturing polyacrylamide gel. Position of the GATA-1 -probe complex (as determined 
from co-runs with extracts from GATA-1 -expressing cell lines) is indicated with an arrow. Lower bands are caused by binding of GATA-1 
proteolytic fragments generated during culture and sample preparation. Lanes 15 through 21 are relatively overexposed as compared with 
lanes 1 through 14.
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For analysis of transferrin receptor- and glycophorin A-expres- 
sion, I to 2 X  106 cells from NBM and MDS patients were labeled 
in the same way with CD71-FITC and GPA/RAM-PE. Samples were 
analyzed on a FACScan (Becton Dickinson). Analysis of data was 
done with the Lysis software program. Windows were designed 
on NBM samples, and also used for the analysis of MDS patient 
material.
Table 3. Summary of Results
RESULTS
Erythroid colony formation and DNA synthesis in re­
sponse to Epo. The clinical data and in vitro colony forma­
tion of the patients with MDS are listed in Table 1. All MDS 
patients except for case 4 showed impaired erythroid colony 
formation after Epo stimulation (mean, 22 ± 50 colonies/ 
10s cells). For NBM, the numbers of erythroid colonies under 
identical conditions varied between 105 and 1,115 per 105 
cells (mean, 454 ± 281; n = 11). Because erythroid colony 
formation is the result of both proliferation and differentia­
tion of progenitor cells, an attempt was made to assess these 
processes separately. The proliferative response to Epo was 
measured at day 3 using the 3H-TdR assay. As can be seen 
in Fig 1, Epo-specilic activation of DNA synthesis was sup­
pressed in all MDS samples as compared with NBM.
Erythroid differentiation and GATA-1 induction. To in­
vestigate the early stages of erythroid differentiation in MDS 
more closely, we analyzed the appearance of morphologi­
cally identifiable erythroid cells. NBM cultures stimulated 
with Epo, Epo + IL-3, or Epo + SCF contained increased 
fractions of erythroid cells at day 3 as compared to control 
cultures with no factor, IL-3» or SCF (Table 2), indicating 
that Epo is necessary for induction of erythroid differentia­
tion in these cells. In MDS cases Epo did not stimulate an 
expansion of the fraction of erythroid cells (Table 2). In 
addition, we assessed the induction of GATA-1 after Epo 
exposure of BM cells. Nuclear extracts of equal cell numbers 
obtained at day 0 and day 3 were assayed for the presence 
of GATA-1 protein (Fig 2). In NBM cells, GATA-binding 
protein was detectable after 3 days in cultures that contained 
Epo (Fig 2, lanes 3, 4, and 5). Under the same conditions 
GATA-1 was only minimally upregulated in certain MDS
FAB
Subtype
Patient
No.
EpoR
Analysis
3H-Thymidine 
Incorporation 
on Epo
STAT5 
Activation on 
Epo
GATA-1 
Activation on 
Epo
RA 1 — Low Low pos/no No
2 — No No No
3 Normal — — —
RARS 4 Normal — — —
RAEB 5 Normal
6 No No No
7 ----------- No No No
8 Normal No No No
9 Normal — -----------
RAEB-t 10 No No No
11 ----------- No Low pos No
12 Normal ----------- — —
13 Normal No No Low
14 Normal No No Low
15 — No No Low
CMML 16 Normal No Low pos/no Low
17 — No No No
18 Normal — — —
19 — Low Low pos/no Low
2 0 — No No No
21 — Low No Low
DNA-binding was detected. To confirm that the protein in 
the complex was indeed STAT5, extracts were incubated 
with different antibodies against STAT5 before the addition 
of probe. With all three antibodies, a partial (Fig 3B, lanes 
3 and 4) or complete (lane 5) supershift was detected, indi­
cating that all complexes contain STAT5 protein. The com­
plete supershift with the «-STAT5B antibody (lane 5) sug­
gests that STAT5B is the predominant Epo-activated form. 
Control incubations with antibodies against ST AT-1 or 
STAT-3 failed to supershift the complex (not shown). The
m67 probe (5'-CATTTCCCGTAAATC-3'), a high-affinity
mutant of the .vj.v-inducible element of the human c-fos
cases (Fig 2, CMML) (6 of 15 cases), whereas in other cases gene,55 was used to assay extracts for the activation of other
GATA-1 was not induced (Fig 2, RAEB) (9 of 15 cases; see 
also Table 3).
These results indicate that MDS marrow cells show an 
impaired Epo response, both with regard to proliferation, as 
evident from the activation of DNA synthesis, and differenti­
ation, as apparent from GATA-1-induction and evaluation 
of morphology.
STAT5 activation in NBM. Induction of STAT5 DNA- 
binding by Epo was assessed in EMSA using the ^-casein 
probe, which specifically recognizes activated STATS.'1-1 In 
a time-course experiment, the probe-protein complex was 
already detectable at 5 minutes, and persisted for 3 hours 
after stimulation of NBM cells (Fig 3A). Also, incubation 
with IL-3 (15 minutes) induced the activation of a STAT5 
DNA-binding activity (Fig 3A, lane 7). The protein-probe 
complex was not present in extracts from cells stimulated 
for 15 minutes without factor (Fig 3B, lane I ). In all NBM 
samples tested (n = 12) Epo-specific induction of STAT5
-proteins. Using this pr 
binding could be detected (not shown).
STATS activation in MDS marrow cells. We then exam­
ined whether STATS was activated after Epo stimulation in 
marrow cells of 15 MDS cases. The results of these studies 
are summarized in Table 3. A representative experiment in­
cluding 5 MDS cases is shown in Fig 4A. No or minimal 
STAT5 activation in response to Epo was seen in these cases, 
whereas IL-3 activated STAT5 normally.
To exclude the possibility that the induction of STATS in 
MDS was quantitatively normal, blit delayed, cells of two 
patients were incubated with Epo for prolonged time periods. 
Even after incubation with Epo for 3 hours, STATS activa­
tion could not be detected, whereas the IL-3-induced signal 
was maximal at 15 minutes (Fig 4B).
Epo-imluced STATS activation in suhpo 
cells. To define the subpopulation of cells in which STATS 
is activated in response to Epo, and to verify the presence
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Fig 3. (A) Activation of /3-casein probe-binding proteins in NBM at different time points. Cells were obtained and extracted immediately 
(lane 1) or after incubation with Epo for 5 (lane 2), 15 (lane 3), 30 (lane 4), 60 {lane 5), or 180 (lane 6) minutes, or after incubation for 15 minutes 
with IL-3 (lane 8). Nuclear extracts of equivalent amounts of NBM cells incubated with the /3-casein probe were run on a nondenaturing 
polyacrylamide gel. Arrow indicates position of STAT5 complex. (B) Identification of STAT-binding proteins activated by Epo in NBM cells. 
Nuclear extracts obtained from nonstimulated cells (lane 1) or from cells stimulated for 15 minutes with Epo (lanes 2 through 5) were incubated 
with the /3-casein probe in the absence (lanes 1 and 2) or presence (lanes 3 through 5} of «-STAT5 antibodies. <*5-1 (lane 3), «-sheep STAT5; 
«5-2 (lane 4), «-human STAT5A; «5-3 (lane 5), «-human STAT5B. Lower arrow indicates position of STAT5 complex, higher arrow the position 
of antibody-containing complexes.
of such a population in MDS, marrow cells were analyzed 
for their expression of CD71 and GPA. These markers distin­
guish successive stages of erythroid differentiation: early 
erytbroblasts are CD71 (transferrin receptor)-positive, but 
glycophorin A (GPA)-negadve (CD71+GPA ), normoblasts 
have acquired GPA (CD71+GPA+), and more mature red 
blood cells have lost the CD71-marker (CD71“GPA+).Sfi
NBM cells were sorted into four R 1
CD71~GPA~, R2 = CD71+GPA~, R3 = CD71+GPA+, and+
ulation of cells shows both IL-3-mediated (Fig 5B, lane 8) 
as well as Epo-mediated STAT5 activation (Fig 5B, lane 9). 
In CD71+GPA+ cells STAT5 is inducible with Epo, but not 
with IL-3 (Fig 5B, lanes 10 through 12). Finally, more ma­
ture CD71~GPA+ cells show no STAT5 activation after Epo 
stimulation (lanes 13 through 15).
Epo-responsive subpopulation in MDS. We then ana­
lyzed the expression pattern of CD71 and GPA for eight 
different MDS patient marrow cells (Fig 6). Although the
CD71 GPA+ (Fig 5A). Morphological analysis of patterns of expression of these surface markers are moreR4 —
the different fractions confirmed the previously established 
correlation between cytological stage and cell-surface phe­
notype (not shown). Sorted fractions were incubated with 
IL-3, Epo, or without factor. The CD71~GPA~ fraction 
shows clear STAT5 activation with IL-3 (Fig 5B, lane 5), 
but not with Epo (Fig 5B, lane 6). The CD71+GPA~ subpop-
heterogeneous among MDS cases, in all instances consider­
able numbers of cells with CD71+GPA~ and CD71+GPA+ 
expression were present. This indicates that the reactive ery­
throid progenitor cell subset has not been eliminated in MDS, 
and thus a quantitative lack of these cells does not explain 
the reduced Epo-induced STAT5 activation in MDS.
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Fig 4» (A) STAT5 activation in MDS patients cells 
after incubation with Epo. Equivalent amounts of 
cells were obtained and extracted after 15 minutes 
of incubation without factor (lanes 1, 4,7,10,13,16), 
with IL-3 (lanes 2# 5, 8,11,14, 17), or with Epo (lanes 
3, 6, 9, 12, 15, 18). Marrow cells used were obtained 
from patient 8 (lanes 1 through 3), patient 13 (lanes 
4 through 6), patient 2 (lanes 7 through 9), patient 1 
(lanes 10 through 12), patient 19 (lanes 13 through 
15), patient 7 (lanes 16 through 18); patient numbers 
correlate to case numbers in Table 1. Nuclear ex­
tracts were incubated with the ¿Ncasein probe. 
Arrow indicates position of STATS complex. (B) Acti­
vation of STAT5 in MDS at different time points. Cells 
from two patients with MDS (patient 13, lanes 1 
through 7; and patient 8, lanes 8 through 14) were 
obtained and extracted after no stimulation (lanes 1 
and 8), or after incubation with Epo for 5 (lanes 2 
and 9), 15 (lanes 3 and 10), 30 (lanes 4 and 11), 60 
(lanes 5 and 12), or 180 minutes (lanes 6 and 13), or 
after incubation for 15 minutes with IL-3 (lanes 7 and 
14). The probe used is the 0-casein probe, and the 
film was relatively overexposed. Arrow indicates po­
sition of STATS complex.
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Fig 5. (A) Flow cytometric analysis of sorted NBM 
cells, CD71~ and GPA“ cells (rectangle 1), CD71H and 
GPA~ cells (rectangle 2), CD71* and GPA* cells (rect­
angle 3), CD71- and GPA* cells (rectangle 4). (B) 
STATS activation in NBM cells sorted for CD71 and 
GPA expression. Cells sorted according to the win­
dows in (A) (0, unsorted cells (lanes 1 through 3]; 1, 
CD7T and GPA~ cells [lanes 4 through 6]; 2, CD714 
and GPA“ cells [lanes 7 through 9]; 3, CD71+ and 
GPA* cells [lanes 10 through 12]; and 4, CD7T and 
GPA* cells [lanes 13 through 15]) were obtained and 
extracted after 15 minutes of incubation without fac­
tor (lanes 1, 4, 1, 10, 13), with IL-3 (lanes 2, 5, 8, 11, 
14), or with Epo (lanes 3, 6, 9, 12, 15). Nuclear ex­
tracts were incubated with the /3-casein probe and 
analyzed for activation of STAT5 on a nondenaturing 
polyacrylamide gel. Arrow indicates position of 
STATS complex.
DISCUSSION by Epo was also impaired in MDS as assessed by the induc­
ía this study, we have analyzed the deficient erythroid ^on GATA-binding proteins, and the appearance of ery- 
maturation in MDS in response to Epo as compared with throid cells in culture. As a first possible mechanism, we 
NBM. Epo-induced DNA synthesis was considerably re- looked for mutations in the EpoR. For instance, mutations 
duced in all cases of MDS tested. Stimulation of maturation in the JAK2 binding domain of the EpoR27,57 lead to abroga-
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Fig 6. Flow cytometric analysis of NBM and MDS patient marrow 
cells. Marrow cells were labeled with CD71-FITC (horizontal axis) and 
GPA/RAM-PE (vertical axis). (A and B), NBM samples; (C), patient 13; 
(D), patient 17; (E), patient 8; (F), patient 1; (G), patient 2; (H), patient 
6; (I), patient 16; (J), patient 7. Patient numbers correlate to case 
numbers in Table 1.
nism of impaired Epo responsiveness (see Table 3, and data 
not shown).
The relation between Epo stimulation and the role of 
GATA-1 is complex, and the hierarchy of cellular events 
during erythroid development has not been fully elucidated. 
However, it is clear that upregulation of GATA-1 expression 
precedes the increase of EpoR mRNA during erythroid dif­
ferentiation.'VJ Studies with GATA-1" mouse embryonic 
stem cells have shown that GATA-1 is essential for erythroid 
cell development.'™’50 GATA-1“ precursors are arrested at 
the proerythroblast stage and undergo premature cell death. 
A low level of GATA-1, present in early progenitors,1<VKW1 
may induce a low level of EpoR expression. A GATA-1 
binding site is present in the EpoR promoter, and this site 
is involved in high-level tissue specific expression of the 
EpoR.61,62 Studies in knock-out mice with a deleted gene of 
either the EpoR or Epo have shown that Epo is not necessary 
for erythroid commitment, but it is essential for the prolifera­
tion and differentiation of committed progenitors.63 Epo 
stimulation of normal erythroid progenitors leads to an 
upregulation of GATA-1 expression (Fig 2-1ii’41). Since we 
have shown that normal levels of EpoR, capable of binding 
their natural ligand, are present on MDS cells,43 it is less 
likely that a primary GATA-1 block and suppression of Epo- 
R expression during differentiation play a dominant role in 
the reduced erythropoiesis.
A lack of STAT5 activation after Epo stimulation was 
apparent in 11 of 15 MDS patients, and it was low in 4 of 
15 patients. In contrast, activation of STATS by Epo could 
always be detected in NBM cells. Although it has been re-
that Epo can activate STATl in certain cell lines/"1
our studies in primary BM cells show only activation of 
STAT5 by Epo. Extended incubation times showed that the 
response is detectable after 5 minutes, it is maximal at 15 
minutes, and it remains up to 3 hours. At none of these time 
points could STATS activation be detected in MDS. Recent 
data using dominant-negative mutants of STAT5,1s and anti­
sense approaches36 underscore the importance of STAT5 for 
mediating proliferation signals of the IL-3 receptor and the 
EpoR, respectively. In our studies, reduced or absent STATS 
activation correlated with an impairment of DNA synthesis 
and with inhibited erythroid colony-forming capacity of 
MDS marrow in all instances (see Ti 3).
The Epo-mediated STAT5 activation could be assigned 
to a specific subpopulation of erythroid 
levels of CD71\ CD71' in c
numbers in all MDS samples tested. Thus, paucity of cells 
with the Epo-responsive phenotype cannot explain the abnor­
mal Epo e, we c 2 that the re
:ed STAT5 response in 
gnaling of the EpoR at an early level.
The experiments reported here are a first step toward un­
derstanding at which level the cascade of the Epo signaling 
is disturbed in MDS. In this report we have used STATS 
and GATA1 as monitors for the activation of the EpoR to 
tion of the Epo-mediated mitogenic response. However, localize the level at which this response is inhibited. The 
screening of the primary sequence of the EpoR of a number nature of these studies is descriptive, as is fre 
of Epo-unresponsive MDS cases (it = I ()) did not provide case
evidence for an abnormal EpoR structure as a general mecha- Nevertheless, the studies cannot
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menologic, because it has been established that inhibition of 
STAT5 and GATA I interferes with Epo-induced cell prolif­
eration and survival.35"’6,30,50 In contrast, this has as yet not 
been reported for Epo-induced MAP kinase and P13K acti­
vation. We do not suggest that the inhibited Epo response 
is an effect specific of STAT5. Failure to activate STAT5, for 
instance, could be related to a deficiency in JAK2 activation. 
Activation of JAK2 may also be necessary for the activation 
of the mi-pathway,65 so that multiple pathways downstream 
of JAK2 in MDS could be deficient, including the ras/ 
MAPK66,67 and PI3K-routes.68"71 Measurements of the activa­
tion of these molecules by immunoprecipitation procedures 
are hampered by the limited amount of patient material avail­
able. Although our data suggest that the inhibited STAT5 
response is a crucial step in the arrest of mitogenesis of 
erythropoietic cells, thus leading to suppressed erythropoie- 
sis, other mechanisms interfering with Epo responsiveness 
should be considered as well. These may involve additional 
molecules known to become activated after stimulation with 
Epo. Notably, the tyrosine phosphatase Syp (SHPTP1D)72 is 
tyrosine-phosphorylated and associates with the EpoR after 
Epo stimulation. For the prolactin receptor it has been shown 
that Syp has a positive effect on signal transduction.73 In 
analogy, inability to activate Syp could lead to an impaired 
Epo response. Alternatively, overactivation of another tyro­
sine phosphatase, hematopoietic cell phosphatase (HCP, 
PTP1C), could downregulate the Epo-mediated signal,74 
leading to a reduced Epo response. In addition, the activation 
of receptors that act upstream in developmental pathways 
may interfere with the function of more downstream recep­
tors.75 All of these signaling pathways deserve a careful anal­
ysis in future studies dealing with the disturbed erythroid 
development in MDS.
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